capecitabine has been researched along with thalidomide in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duncton, MA; Emerling, DE; Kelly, MG; Nguyen, MT; Vincent, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amato, RJ | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Amato, RJ; Rawat, A | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B | 1 |
| Lim, ST; Ong, S; Quek, R | 1 |
| Curtiss, FR | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Amato, RJ; Khan, M | 1 |
| Amato, RJ; Mohammad, T | 1 |
| Harshman, LC; Li, M; Srinivas, S | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG | 1 |
| Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA | 1 |
| Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC | 1 |
| Fan, WF; Liu, FY; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Li, CH; Ma, TH; Shi, SB; Tang, XY | 1 |
| Cao, KI; Kirova, YM | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Hao, XB; He, ZH; Hong, T; Huang, F; Huang, MZ; Jiang-Zheng, Z; Lei, JH; Lu, YD; Wang-Yuan, Z | 1 |
| Chu, Y; Li, Y; Song, R; Xu, F | 1 |
| Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J | 1 |
5 review(s) available for capecitabine and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Thalidomide therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Thalidomide | 2003 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide | 2015 |
10 trial(s) available for capecitabine and thalidomide
| Article | Year |
|---|---|
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thalidomide; Treatment Outcome | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Texas; Thalidomide; Treatment Outcome | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nephrectomy; Survival Rate; Thalidomide; Treatment Outcome | 2008 |
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Germany; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Thalidomide | 2010 |
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Thalidomide | 2013 |
Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease-Free Survival; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
9 other study(ies) available for capecitabine and thalidomide
| Article | Year |
|---|---|
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Topics: Amidohydrolases; Carbamates; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Male; Megestrol; Thalidomide; Treatment Outcome | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide | 2012 |
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fluorouracil; Follow-Up Studies; Humans; Male; Prednisone; Prostatic Neoplasms; Retrospective Studies; Thalidomide | 2012 |
Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Thalidomide; Treatment Outcome | 2018 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult | 2018 |